Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Nasus Pharma Ltd. ( (NSRX) ).
Nasus Pharma Ltd., a company involved in the pharmaceutical industry, announced changes in its board of directors on September 3, 2025. Dan Teleman, the Chief Executive Officer, has been appointed as a Class III director, filling a vacancy on the board. His term will last until the annual general meeting of shareholders in 2028. Additionally, the board has replaced David Silberman with Ronnie Hershman on the Compensation Committee, indicating a strategic shift in its governance structure.
More about Nasus Pharma Ltd.
Average Trading Volume: 65,486
Find detailed analytics on NSRX stock on TipRanks’ Stock Analysis page.